| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
CLDX
Celldex
|
Jun 14, 2026 | BUY |
Strong Buy
+20.6% avg upside
28 analysts
|
$44.00
35.67% Upside
|
+0.8% |
|
ABVX
Abivax SA Sponsored ADR
|
Jun 03, 2026 | BUY |
Strong Buy
+20.7% avg upside
15 analysts
|
$136.00
37.21% Upside
|
+11.1% |
|
VERA
Vera Therapeutics
|
Jun 02, 2026 | BUY |
Strong Buy
+91.0% avg upside
19 analysts
|
$88.00
150.87% Upside
|
+12.2% |
|
AVTX
Avalo Therapeutics
|
Apr 08, 2026 | BUY |
Strong Buy
+265.1% avg upside
19 analysts
|
$48.00
226.57% Upside
|
+13.5% |
|
PALI
Palisade Bio
|
Apr 08, 2026 | BUY |
Strong Buy
+1347.1% avg upside
15 analysts
|
$7.00
274.38% Upside
|
-5.9% |
|
PHVS
Pharvaris
|
Apr 08, 2026 | BUY |
Strong Buy
+37.2% avg upside
14 analysts
|
$42.00
27.95% Upside
|
+21.2% |
|
DNTH
Dianthus Therapeutics
|
Apr 08, 2026 | BUY |
Strong Buy
+8.8% avg upside
29 analysts
|
$98.00
18.83% Upside
|
-5.7% |
|
IMVT
Immunovant
|
Apr 06, 2026 | BUY |
Strong Buy
+8.9% avg upside
24 analysts
|
$47.00
33.01% Upside
|
+39.5% |
|
MLTX
MoonLake Immunotherapeutics
|
Mar 23, 2026 | BUY |
Strong Buy
+51.6% avg upside
20 analysts
|
$24.00
24.97% Upside
|
+13.8% |
|
APGE
Apogee Therapeutics
|
Jan 07, 2026 | HOLD |
Strong Buy
+28.5% avg upside
19 analysts
|
— | +12.0% |
|
VRTX
Vertex Pharmaceuticals
|
Jan 06, 2026 | BUY |
Strong Buy
-2.6% avg upside
61 analysts
|
$548.00
21.40% Upside
|
-2.0% |
|
KYMR
Kymera Therapeutics
|
Jan 06, 2026 | HOLD |
Strong Buy
+8.9% avg upside
36 analysts
|
— | +22.4% |
|
MDGL
Madrigal Pharmaceuticals
|
Jan 06, 2026 | HOLD |
Strong Buy
-5.8% avg upside
31 analysts
|
— | -9.4% |
|
ARGX
Argenx Se
|
Nov 24, 2025 | HOLD |
Strong Buy
-15.8% avg upside
46 analysts
|
— | -2.7% |
|
NTLA
Intellia Therapeutics
|
Nov 11, 2025 | HOLD |
Strong Buy
+151.9% avg upside
37 analysts
|
— | +19.0% |
|
IVA
Inventiva
|
Nov 05, 2025 | BUY |
Strong Buy
+350.1% avg upside
16 analysts
|
$13.00
264.19% Upside
|
-80.7% |
|
INSM
Insmed
|
Aug 14, 2025 | BUY |
Strong Buy
+82.2% avg upside
36 analysts
|
$173.00
80.55% Upside
|
-22.9% |
|
ALNY
Alnylam Pharma
|
Aug 04, 2025 | HOLD |
Strong Buy
+23.6% avg upside
51 analysts
|
— | -32.6% |
|
BBIO
BridgeBio Pharma
|
Jun 16, 2025 | BUY |
Strong Buy
+38.7% avg upside
34 analysts
|
$49.00
26.13% Downside
|
+62.0% |
|
SRPT
Sarepta Therapeutics
|
Jun 16, 2025 | HOLD |
Buy
+244.5% avg upside
49 analysts
|
— | -24.8% |
|
ANAB
AnaptysBio
|
May 21, 2025 | BUY |
Strong Buy
+26.1% avg upside
26 analysts
|
$25.00
56.54% Downside
|
+335.5% |
|
SYRE
Spyre Therapeutics
|
Mar 17, 2025 | BUY |
Strong Buy
-15.4% avg upside
23 analysts
|
$27.00
69.51% Downside
|
+193.6% |
|
INCY
Incyte
|
Mar 17, 2025 | BUY |
Strong Buy
+1.0% avg upside
47 analysts
|
$84.00
14.54% Downside
|
+51.9% |
|
CRNX
Crinetics Pharmaceuticals
|
Feb 03, 2025 | HOLD |
Strong Buy
+121.2% avg upside
20 analysts
|
— | +28.8% |
|
ZBIO
Zenas BioPharma, Inc.
|
Feb 03, 2025 | BUY |
Strong Buy
+102.2% avg upside
11 analysts
|
$19.00
3.90% Downside
|
+166.1% |
|
ORKA
Oruka Therapeutics
|
Feb 03, 2025 | BUY |
Strong Buy
+61.8% avg upside
16 analysts
|
$20.00
72.29% Downside
|
+152.2% |
|
VRDN
Viridian Therapeutics
|
Jun 10, 2024 | BUY |
Strong Buy
+103.7% avg upside
32 analysts
|
$29.00
74.34% Upside
|
+26.2% |
|
IONS
Ionis Pharmaceuticals
|
Apr 09, 2024 | BUY |
Strong Buy
+13.3% avg upside
43 analysts
|
$58.00
21.66% Downside
|
-35.2% |
|
ROIV
Roivant Sciences
|
Feb 14, 2024 | BUY |
Strong Buy
+2.5% avg upside
17 analysts
|
— | -6.7% |
|
CRSP
Crispr Therapeutics AG
|
Feb 14, 2024 | HOLD |
Buy
+39.1% avg upside
41 analysts
|
— | -37.1% |
|
STTK
Shattuck Labs
|
Oct 25, 2023 | BUY |
Strong Buy
+369.1% avg upside
14 analysts
|
$4.00
19.23% Downside
|
-18.6% |
|
AFMDQ
Affimed
|
Aug 10, 2023 | BUY |
Buy
+12648900.0% avg upside
15 analysts
|
$60.00
59999899.90% Upside
|
· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.